DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ddctsh/victoza_obesity) has announced the addition of the "Victoza (Obesity) - Forecast and Market Analysis to 2022" report to their offering.
After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.
Victoza was approved by the FDA in 2010 as a once-daily injection to treat type 2 diabetes in adults. It is also available in the 5EU, as well as in Canada, for the same indication and use. It is not expected to be a presence in the Japanese market, as Novo Nordisk has not indicated any plans for expansion there, or in the Brazilian market, as diabetic therapies in this market are OTC.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Victoza (liraglutide)
For more information visit http://www.researchandmarkets.com/research/ddctsh/victoza_obesity